Negma Laboratories

Negma Laboratories is a French pharmaceutical company headquartered in Magny-les-Hameaux, specializing in the fields of rheumatology, neurology, and cardiology. Established in 1988, the company built a significant market presence with products such as Art 50 (diacerein) for osteoarthritis and Veinamitol for venous insufficiency. In 2007, Negma was acquired by the Indian pharmaceutical giant Wockhardt for approximately $265 million, marking one of the largest overseas acquisitions by an Indian pharma company at the time. The acquisition provided Wockhardt with a robust commercial platform and a portfolio of 172 patents in Europe. Today, Negma operates as a key subsidiary of Wockhardt France, focusing on the commercialization of specialty branded medicines and established products in the French healthcare market.